Abstract
Background: Fumitremorgins are mycotoxins but can also inhibit cancer cells and reverse their drug resistance.
Objective: The bioactivity of prenylated cyclo-Trp-Pro dipeptides and their derivatives concerning their application in anti-cancer therapies will be discussed.
Methods: Reports on the discovery and assessment of this class of fungal compounds are compiled from literature using Google Scholar and PubMed. The bioactivities of the natural compounds are discussed with the aim of their improvement for cancer therapy.
Results: Although a number of compounds of this class have been found, only a minority of them showed bioactivity in the applied bioassays. Fumitremorgins and related compounds are active against various cancer cells but they are also mycotoxins. Some of these natural compounds can arrest cancer cells in their cell cycle and some can block ABC-transporters and reverse resistance in chemotherapy. Structure activity relationships have been deduced leading to the prediction of highly active compounds. Several easily accessible derivatives of these natural products have been discovered being highly selective and non-toxic.
Conclusion: Sophisticated screening methods, high throughput screening, metabolic engineering, and synthetic biology are novel and promising technologies for the search for highly active drugs. Rapid gene sequencing in combination with engineered biosynthetic pathways should contribute substantially to novel pharmaceutics.
Keywords: Diketopiperazines, cyclic dipeptides, fumitremorgin, cyclotryprostatin, norgeamide, anti-cancer, drug resistance, ABCG2 transporter
Current Medicinal Chemistry
Title:Fumitremorgins and Relatives – From Tremorgenic Compounds to Valuable Anti-Cancer Drugs
Volume: 25 Issue: 2
Author(s): Wolf-Rainer Abraham*
Affiliation:
- Helmholtz Centre for Infection Research, Chemical Microbiology, Braunschweig,Germany
Keywords: Diketopiperazines, cyclic dipeptides, fumitremorgin, cyclotryprostatin, norgeamide, anti-cancer, drug resistance, ABCG2 transporter
Abstract: Background: Fumitremorgins are mycotoxins but can also inhibit cancer cells and reverse their drug resistance.
Objective: The bioactivity of prenylated cyclo-Trp-Pro dipeptides and their derivatives concerning their application in anti-cancer therapies will be discussed.
Methods: Reports on the discovery and assessment of this class of fungal compounds are compiled from literature using Google Scholar and PubMed. The bioactivities of the natural compounds are discussed with the aim of their improvement for cancer therapy.
Results: Although a number of compounds of this class have been found, only a minority of them showed bioactivity in the applied bioassays. Fumitremorgins and related compounds are active against various cancer cells but they are also mycotoxins. Some of these natural compounds can arrest cancer cells in their cell cycle and some can block ABC-transporters and reverse resistance in chemotherapy. Structure activity relationships have been deduced leading to the prediction of highly active compounds. Several easily accessible derivatives of these natural products have been discovered being highly selective and non-toxic.
Conclusion: Sophisticated screening methods, high throughput screening, metabolic engineering, and synthetic biology are novel and promising technologies for the search for highly active drugs. Rapid gene sequencing in combination with engineered biosynthetic pathways should contribute substantially to novel pharmaceutics.
Export Options
About this article
Cite this article as:
Abraham Wolf-Rainer *, Fumitremorgins and Relatives – From Tremorgenic Compounds to Valuable Anti-Cancer Drugs, Current Medicinal Chemistry 2018; 25 (2) . https://dx.doi.org/10.2174/0929867324666170724103410
DOI https://dx.doi.org/10.2174/0929867324666170724103410 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<i>Momordica balsamina L</i>.: An Appraisal on Morphology, Ecological Diversity,
Phytochemistry, Pharmacological and Biotechnological Applications
Current Traditional Medicine Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design Entosis: Cell-in-Cell Formation that Kills Through Entotic Cell Death
Current Molecular Medicine A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin
Current Drug Targets Proteinases as Biomarkers in Breast Cancer Prognosis and Diagnosis
Mini-Reviews in Medicinal Chemistry Epidemiology and Pathology of Malignant Mesothelioma
Current Respiratory Medicine Reviews Design and Development of Nanoemulsion Systems Containing Interferon Gamma
Protein & Peptide Letters Micro/Nanoparticle Design and Fabrication for Pharmaceutical Drug Preparation and Delivery Applications
Current Drug Therapy Comparative Study of Aromatase Enzyme Inhibition by Synthetic and Natural Ligand: Molecular Modeling and Conceptual DFT Investigation
Current Enzyme Inhibition Influence of Polymer Molecular Weight on in-vitro Characteristics and Cytotoxicity of Fulvestrant Loaded Nanoparticles
Current Drug Therapy Design, Synthesis and Antitumor Activity of Dimeric Bile Acid-Amino Acid Conjugates
Letters in Organic Chemistry Meet Our Editorial Board Member
Current Drug Therapy Molecularly Imprinted Solid Phase Extraction Before Capillary Electrophoresis for the Analysis of Estrogens in Serum Samples
Current Analytical Chemistry Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Current Cancer Drug Targets Imaging of HER-2 Overexpression in Tumors for Guiding Therapy
Current Pharmaceutical Design Anticancer Alkylphospholipids: Mechanisms of Action, Cellular Sensitivity and Resistance, and Clinical Prospects
Current Pharmaceutical Design Editorial [Hot Topic: Cancer Vaccine and Immunotherapy (Executive Editor: Farid Saleh)]
Current Pharmaceutical Design Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets Data-driven Approach to Detect and Predict Adverse Drug Reactions
Current Pharmaceutical Design Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry